Exploring the link between dietary inflammatory index, inflammatory biomarkers, and sleep quality in adults with obesity: a pilot investigation

Introduction

Obesity, a multifaceted non-communicable condition, is characterized by an excessive energy balance, increased adipose tissue, and chronic low-grade inflammation [1]. The prevalence of obesity has alarmingly doubled globally over the last four decades, cutting across gender, age, socioeconomic status, and ethnicity [2]. This rising trend highlights the urgent need for novel strategies in obesity research, evaluation, management, and treatment [3].

Inflammation, a response to cellular injury, facilitates tissue repair and neutralizes harmful agents. It involves the release of various chemical mediators [4]. Persistent, unaddressed inflammation can lead to chronic conditions, contributing to diseases like type 2 diabetes, dyslipidemia, metabolic syndrome, cardiovascular diseases, and depression [5].

Recent studies have also linked inflammation to sleep quality. Inflammatory mediators, particularly cytokines, are crucial in the relationship between sleep and the immune system [6]. Research has shown a correlation between sleep disturbances and increased inflammatory markers [7]. Poor sleep quality can disrupt immune function, elevating markers like C-reactive protein (CRP) [8, 9].

The anti-inflammatory properties of various nutrients have been documented [10,11,12]. The Dietary Inflammatory Index (DII), developed by Shivappa et al. (2014), assesses the inflammatory potential of diets, based on an analysis of 1943 studies across 11 countries. This index, comprising 45 dietary components, categorizes diets as pro-inflammatory or anti-inflammatory [10].

Despite the expanding research on obesity treatment, there is a lack of studies on the impact of dietary inflammation on inflammatory markers and sleep quality in people with obesity. The aim of our pilot investigation was to explore the relationship between the inflammatory index of the diet consumed by adults with obesity and, inflammatory biomarkers, and sleep quality.

Materials and Methods

This pilot investigation was conducted at the diet outpatient clinic of a state hospital in Malatya/Turkey from November 2021 to May 2022.

Sample of the study

This study was conducted on 176 individuals (103 women, 73 men) who applied to the diet outpatient clinic of a public hospital in Turkey between November 2021 and May 2022. Based on the number of applicants, a programme called ‘Sample Size Calculator’ was used and the sample size was determined as 121 with a 95% confidence interval and a 5% margin of error. During the research process, 52 of the participants refused to participate in the study, resulting in 124 individuals successfully completing the study.

Eligibility for the study was confined to individuals aged 19–65 years with a Body Mass Index (BMI) of 30–40 kg/m2, free from chronic conditions such as diabetes, hypertension, dyslipidemia, cancer, or chronic renal failure. Exclusion criteria encompassed recent dietary program adherence, nutritional supplement intake, inflammatory disease diagnosis, or severe psychiatric disorders. Pregnancy and breastfeeding were also exclusion criteria. Essential for inclusion was voluntary participation without recent engagement in dietary interventions or supplement consumption.

Data collection instruments

Data Collection Form: In this form consisting of four sections, socio-demographic information, sleep quality through Pittsburgh Sleep Quality Index and three-day dietary intake record were collected. It was administered through direct interviews. Dietary intake record and anthropometric measurements were collected by the researcher, while routine biochemical measurements were obtained from existing participant records.

Dietary intake records

To evaluate dietary patterns and calculate DII scores, participants recorded their food intake over three days, including one weekend day. Detailed instructions and examples were provided for accurate record-keeping.

Pittsburgh Sleep Quality Index (PSQI)

The PSQI, adapted for Turkish populations by Ağargün et al. (1996), assessed sleep quality over the past month. It includes 24 questions, with 19 self-reported and 5 completed by a spouse or roommate. Each item is scored from 0 to 3, with a maximum total score of 21. A score above five indicates poor sleep quality [13].

Biochemical measurements

Specific biochemical tests were routinely ordered for participants by an internist. These included fasting blood glucose, triglycerides, total cholesterol, LDL-cholesterol, and HDL-cholesterol. Additionally, inflammatory markers such as CRP, leukocyte, lymphocyte, monocyte, neutrophil, and eosinophil levels were measured. These parameters were analyzed using spectrophotometry on the Beckman Coulter AU640, with LDL cholesterol calculated using the Friedewald formula [14].

Computation of the Dietary Inflammatory Index (DII)

The DII, developed by Shivappa et al. (2014), evaluates the inflammatory potential of diets. It involves calculating z-scores for consumed nutrients, based on mean daily intakes and standard deviations established from national nutritional research datasets across various populations (Shivappa et al., 2014). The process entailed transforming z-scores to percentile scores, which were then adjusted (doubled and decremented by one) for symmetric distribution. These adjusted values were multiplied by customised effect scores for each nutrient. The DII is obtained by summing these values, representing the inflammatory potential of the diet [10]. In this study, data for 32 nutrient components was available for DII calculation. The customised effect scores, global average daily intakes, and standard deviation (SD) values pertinent to the DII computation for these nutrients are delineated in Table 1.

Table 1 Nutrient Parameters for Dietary Inflammatory Index Calculation: Customised Effect Scores, Global Average Daily Intakes and Standard Deviations (Shivappa et al. 2014).
Full size table

Statistical analysis

Data analysis was conducted using IBM SPSS software (Version 22.0), with dietary consumption records assessed via the BeBIS 8.2 program. Descriptive statistics, including arithmetic mean, standard deviation, range, frequency, and percentage, were computed. DII scores were categorised into quartiles, with Q1 being the most anti-inflammatory and Q4 being the most pro-inflammatory.

The normality of data distribution was evaluated using histograms, Q-Q plots, and the Kolmogorov-Smirnov test. Categorical variables were analyzed with the Pearson chi-square test. The t-test and Analysis of Variance (ANOVA) were applied for independent group differences when parametric test assumptions were met. For non-parametric conditions, the Mann-Whitney U and Kruskal Wallis tests were employed. Variance homogeneity was assessed using Levene’s test. Statistical significance was set at a p-value threshold of less than 0.05.

Results

In this part of the study, the findings obtained by analysing the data obtained as a result of this research conducted with 124 participants are presented. Information about the general characteristics of the participants in the Dietary Inflammatory Index quartiles is given in Table 2.

Table 2 General characteristics of participants in the dietary inflammatory index quartiles.
Full size table

The mean age of the participants was 42.2 ± 11.0 years. 39.5% of the participants were male and 60.5% were female; 35.5% were primary school graduates, 18.5% were high school graduates and 18.5% were university graduates. While 12.1% of the participants were not working, 11.3% were civil servants, 48.4% were housewives, 84.7% were married and 15.3% were single. No significant relationship was found between the general characteristics of the participants and the quartile groups (p > 0.05).

The distribution of anthropometric, biochemical and sleep quality measurements of the participants according to quartile groups is given in Table 3.

Table 3 Distribution of anthropometric, biochemical and sleep quality measurements of the participants according to quartile groups.
Full size table

It was found that as the inflammatory score of the diet consumed by the participants increased, body weight, BMI increased significantly and body fluid ratio decreased significantly (p < 0.05). In addition, CRP, one of the biochemical parameters, was found to increase significantly with the increase in the inflammatory score of the diet (p < 0.05).

Table 4 shows the vials for the comparison of anthropometric measurements, biochemical measurements, sleep quality scores and dietary ınflammatory ındex scores of the participants.

Table 4 Comparison of anthropometric measurements. biochemical measurements. sleep quality scores. and dietary ınflammatory ındex scores of the participants.
Full size table

A negative weak significant correlation was found between the increase in age of the participants and DII (p < 0.05). A negative weak significant correlation was found between body water ratio, total cholesterol and monocyte level and DII score, while a positive weak significant correlation was found with CRP (p < 0.05).

Discussion

In this pilot study involving 124 individuals with obesity, the relationship between the inflammatory index of diets consumed and inflammation and sleep quality problems in this population was examined.

Obesity is a complex health condition associated with increased levels of inflammation and poor sleep quality. In a study conducted by Göktaş et al. it was found that 81.3% of individuals with obesity had poor sleep quality [15]. In addition, in a study conducted by Altın et al. it was found that sleep quality worsened as the BMI of the participants increased and 75% of individuals with obesity experienced poor sleep quality [16]. The findings of this study, in line with previous studies in the literature, reveal that poor sleep quality is highly prevalent in people with obesity.

Dietary habits and culture significantly impact anthropometric measurements. Research examining the relationship between diet’s inflammatory score and anthropometric measurements found higher BMI and waist/hip ratios in individuals following pro-inflammatory diets [17]. Similarly, another study reported increased BMI, waist circumference, and waist/height ratios in those consuming a pro-inflammatory diet [18]. An investigation focusing on adults’ BMI and waist circumference in relation to their DII scores observed that those with higher DII scores had significantly larger waist circumferences, although no significant correlation with BMI was found [19]. In this study, it was found that the BMIs of those who were fed with lower DII scores were significantly lower and the findings of the study were found to be consistent with the literature.

In examining the association between DII scores and CRP, a key inflammatory marker, Shivappa et al. (2018) found a strong positive correlation [20]. This is echoed in a study by the Korea National Health and Nutrition Examination Survey (KNHANES, 2015), which showed a positive correlation between DII scores and CRP levels [21]. Similarly, a cross-sectional study involving 1992 adults revealed that higher DII scores were associated with elevated CRP values [19]. In the present study, the CRP levels of the groups fed with higher DII scores were found to be significantly increased and the findings of the study were found to be consistent with the literature.

The relationship between the DII and sleep quality has been a subject of varying research findings. Setayesh et al. (2021) identified a significant link between high DII scores and poor sleep quality, suggesting that diets with higher inflammatory potential may negatively impact sleep [22]. In contrast, a study focusing on university students by Masaad et al. (2021) did not find a statistically significant association between DII scores and sleep quality [23]. Interestingly, in this study, no significant association was found between the inflammatory score of the anti-inflammatory diet consumed and sleep quality. What is even more interesting in this study is that the consumption of diets with anti-inflammatory properties was not associated with sleep quality. However, a significant proportion of the study population had poor sleep quality, and as DII scores increased, a decline in sleep quality was noted, although not significantly. The simultaneous occurrence of high DII scores and increased poor sleep quality, especially in people with obesity, suggests that more detailed studies should be conducted on this subject.

Strengths and limitations

The strengths of this study address an important health issue by analysing the relationships between DII, obesity, inflammation biomarkers and sleep quality based on current literature. The study controlled for variables that may affect the results by excluding individuals with chronic diseases. The study revealed a clear association between the consumption of diets with high DII scores and inflammatory markers and obesity. These findings provide valuable guidance for the development of targeted nutritional interventions, focusing on dietary factors associated with obesity. In addition to important findings, this study also has some limitations. Due to the small sample size, the significance of effects on individual parameters is limited; therefore, it was planned as a pilot study. The results obtained in this study, together with a review of the literature, reveal strong associations between dietary inflammatory load and critical determinants of human life such as age, BMI and inflammation. It was found that there is a relationship between the DII and sleep quality, although not directly, and that poor sleep quality increases with the presence of obesity.

Conclusion

In this study involving people with obesity, an association was found between BMI and CRP and dietary inflammatory index scores. This association implies that dietary intake may influence the development of obesity through inflammatory pathways and that both obesity and inflammation may adversely affect humans. Consequently, it is imperative to promote the consumption of anti-inflammatory diets to counteract inflammation. Furthermore, it is recommended that future research should be strategically designed and conducted to examine in more depth the reciprocal relationships between obesity, inflammation, sleep quality and anti-inflammatory diets.

Related Articles

Type 2 immunity in allergic diseases

Significant advancements have been made in understanding the cellular and molecular mechanisms of type 2 immunity in allergic diseases such as asthma, allergic rhinitis, chronic rhinosinusitis, eosinophilic esophagitis (EoE), food and drug allergies, and atopic dermatitis (AD). Type 2 immunity has evolved to protect against parasitic diseases and toxins, plays a role in the expulsion of parasites and larvae from inner tissues to the lumen and outside the body, maintains microbe-rich skin and mucosal epithelial barriers and counterbalances the type 1 immune response and its destructive effects. During the development of a type 2 immune response, an innate immune response initiates starting from epithelial cells and innate lymphoid cells (ILCs), including dendritic cells and macrophages, and translates to adaptive T and B-cell immunity, particularly IgE antibody production. Eosinophils, mast cells and basophils have effects on effector functions. Cytokines from ILC2s and CD4+ helper type 2 (Th2) cells, CD8 + T cells, and NK-T cells, along with myeloid cells, including IL-4, IL-5, IL-9, and IL-13, initiate and sustain allergic inflammation via T cell cells, eosinophils, and ILC2s; promote IgE class switching; and open the epithelial barrier. Epithelial cell activation, alarmin release and barrier dysfunction are key in the development of not only allergic diseases but also many other systemic diseases. Recent biologics targeting the pathways and effector functions of IL4/IL13, IL-5, and IgE have shown promising results for almost all ages, although some patients with severe allergic diseases do not respond to these therapies, highlighting the unmet need for a more detailed and personalized approach.

Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects

The muscular system plays a critical role in the human body by governing skeletal movement, cardiovascular function, and the activities of digestive organs. Additionally, muscle tissues serve an endocrine function by secreting myogenic cytokines, thereby regulating metabolism throughout the entire body. Maintaining muscle function requires iron homeostasis. Recent studies suggest that disruptions in iron metabolism and ferroptosis, a form of iron-dependent cell death, are essential contributors to the progression of a wide range of muscle diseases and disorders, including sarcopenia, cardiomyopathy, and amyotrophic lateral sclerosis. Thus, a comprehensive overview of the mechanisms regulating iron metabolism and ferroptosis in these conditions is crucial for identifying potential therapeutic targets and developing new strategies for disease treatment and/or prevention. This review aims to summarize recent advances in understanding the molecular mechanisms underlying ferroptosis in the context of muscle injury, as well as associated muscle diseases and disorders. Moreover, we discuss potential targets within the ferroptosis pathway and possible strategies for managing muscle disorders. Finally, we shed new light on current limitations and future prospects for therapeutic interventions targeting ferroptosis.

Implantation of engineered adipocytes suppresses tumor progression in cancer models

Tumors exhibit an increased ability to obtain and metabolize nutrients. Here, we implant engineered adipocytes that outcompete tumors for nutrients and show that they can substantially reduce cancer progression, a technology termed adipose manipulation transplantation (AMT). Adipocytes engineered to use increased amounts of glucose and fatty acids by upregulating UCP1 were placed alongside cancer cells or xenografts, leading to significant cancer suppression. Transplanting modulated adipose organoids in pancreatic or breast cancer genetic mouse models suppressed their growth and decreased angiogenesis and hypoxia. Co-culturing patient-derived engineered adipocytes with tumor organoids from dissected human breast cancers significantly suppressed cancer progression and proliferation. In addition, cancer growth was impaired by inducing engineered adipose organoids to outcompete tumors using tetracycline or placing them in an integrated cell-scaffold delivery platform and implanting them next to the tumor. Finally, we show that upregulating UPP1 in adipose organoids can outcompete a uridine-dependent pancreatic ductal adenocarcinoma for uridine and suppress its growth, demonstrating the potential customization of AMT.

Role of pancreatic lipase inhibition in obesity treatment: mechanisms and challenges towards current insights and future directions

The worldwide health emergency of obesity is closely connected to how dietary fats are metabolized, whereas the process is significantly influenced by pancreatic lipase (PL), an enzyme critical for lipid hydrolysis into fatty acids. This narrative review employs a methodological approach utilizing literature searches of PubMed data up to March 2024. The search term criteria encompasses keywords related to the role, mechanism, challenges, and current and future treatments of pancreatic lipase in obesity with an overall references is 106. This paper offers a comprehensive explanation of the role of PL, underlining its significance in the digestive process and lipid imbalances that contribute to obesity and by extension, its impact on obesity development and progression. Additionally, it delves into the dual functionality of the pancreas, emphasizing its impact on metabolism and energy utilization which, when dysregulated, promotes obesity. A focal point of this review is the investigation into the efficacy, challenges, and adverse effects of current pancreatic lipase inhibitors, with orlistat being highlighted as a primary current drug delivery. By discussing advanced obesity treatments, including the exploration of novel anti-obesity medications that target specific biological pathways, this review underscores the complexity of obesity treatment and the necessity for a multifaceted approach. In conclusion, this paper emphasizing the importance of understanding the role of enzymes like pancreatic lipase mechanistic and adopting a multidisciplinary approach to treatment and side effects of current obesity drugs and explore new emerging therapeutic strategies for more effective obesity management.

Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia

X-linked hypophosphataemia (XLH) is a rare metabolic bone disorder caused by pathogenic variants in the PHEX gene, which is predominantly expressed in osteoblasts, osteocytes and odontoblasts. XLH is characterized by increased synthesis of the bone-derived phosphaturic hormone fibroblast growth factor 23 (FGF23), which results in renal phosphate wasting with consecutive hypophosphataemia, rickets, osteomalacia, disproportionate short stature, oral manifestations, pseudofractures, craniosynostosis, enthesopathies and osteoarthritis. Patients with XLH should be provided with multidisciplinary care organized by a metabolic bone expert. Historically, these patients were treated with frequent doses of oral phosphate supplements and active vitamin D, which was of limited efficiency and associated with adverse effects. However, the management of XLH has evolved in the past few years owing to the availability of burosumab, a fully humanized monoclonal antibody that neutralizes circulating FGF23. Here, we provide updated clinical practice recommendations for the diagnosis and management of XLH to improve outcomes and quality of life in these patients.

Responses

Your email address will not be published. Required fields are marked *